The United States Food and Drug Administration (FDA) approved a nerve disease treatment jointly created by AstraZeneca plc and Ionis Pharmaceutical Inc.
The drug in question, titled 'Wainua,' is the only self-administrable drug capable of treating the hereditary "polyneuropathy of hereditary transthyretin-mediated amyloidosis" (hATTR-PN) in adults, a disease which leads to motor disability caused by nerve damage. Without treatment, the disease generally results in a fatality within 10 years. FDA's approval was based on the positive 35-week NEURO-TTRansform Phase III trial.
"The FDA approval of Wainua marks an important milestone for people living with this affliction, who will now have an effective, well-tolerated treatment that can be self-administered via auto-injector to combat this devastating disease," CEO of Ionis Brett P. Monia said.
